GCP · Blog

GCP Blog — Field notes from clinical research

October 2026 Edition

The Lead Story

The Lead
GCP14 min read

21 CFR 312: a map of the IND regulation, subpart by subpart

21 CFR 312 is the FDA regulation for investigational new drug applications (INDs). People usually meet it one section at a time: a monitor cites 312.62(b), a contract mentions 312.52, a regulatory lead asks whether a study needs an IND at all. This page is a map of the whole part. It shows which subpart applies at which point in a drug's development, who each one binds, and where the section numbers people search for sit.

Read the full piece

Recent dispatches

GCP

Clinical Trial Timelines: A GCP Milestone Model for Planning Around the Months You Actually Lose

Most "how long does a clinical trial take" pages give you a phase-duration table and stop.

Read
GCP

Patient Recruitment in Clinical Trials: A GCP Compliance Guide to Ads, Inducement, Pre-Screening, and Consent Timing

Most "how to improve recruitment" content treats enrollment as a conversion problem: better channels, sharper messaging, loyalty for retention.

Read
GCP

Patient Retention in Clinical Trials: A GCP Quality Control, Not a Tip List

Most "patient retention in clinical trials" guides read like a customer-service checklist: set expectations, communicate often, reimburse travel, be person-centric.

Read
GCP

EU Clinical Trial Regulation 536/2014: The CTIS Submission Workflow, Assessment Clocks, and RFI Deadlines

This guide treats CTR 536/2014 the way a clinical-ops or regulatory-affairs reader actually meets it: as a sequence of portal actions and countdowns.

Read
GCP

The FDA Form 483 Response for Clinical Sites and Sponsors: A 15-Day Playbook and Year-Round Inspection-Readiness Guide

The clinical-site internet has a problem: nearly every "how to respond to a 483" page is written for a drug-manufacturing plant.

Read
GCP

ICH E9 for Non-Statisticians: The Operational Contract That Locks Your Trial's Question Before Unblinding

For clinical-ops, CRAs, data managers, and QA staff, the most useful way to read ICH E9 is operational, not mathematical.

Read
GCP

Clinical Study Report vs. ClinicalTrials.gov Results: Two Deliverables, Two Clocks, and How to Pick the Right CSR Format

If your team has ever posted summary results to ClinicalTrials.gov, breathed out, and assumed end-of-study reporting was finished, this article is for you.

Read
GCP

ICH E3 Clinical Study Report Template: Pick the Tier First, Then Defend the Section Map

A clinical study report (CSR) is the document where a trial either holds together or falls apart under review.

Read
GCP

FDA BIMO Inspection Prep: An Oversight Stress-Test, Not a Binder Checklist

A BIMO inspection feels procedural from the outside: a preannounced visit, a request for records, a Form 483 at the close.

Read

The archive

110 pieces

The FDA IND Application as a Three-Pillar Safety Dossier: 21 CFR 312.23 Contents, the 30-Day Clock, and the Sponsor-Investigator Traps That Trigger a Clinical Hold

ICH E8(R1) in Practice: Turning Critical-to-Quality Factors into Risk-Proportionate Controls and an E6(R3) RBQM Hand-off

MHRA GCP Inspection Findings as a Risk Map: Map the Recurring Themes to ICH E6(R3) and Self-Inspect Before They Cite You

GCP Audit Checklist: Two Lists, Not One — Site (BIMO) vs. Vendor/CRO, Graded by Subject Protection and Data Integrity

The Visit-Type-Aware Clinical Trial Monitoring Visit Checklist: SQV, SIV, IMV, COV, and Inspection Prep, Mapped to GCP

Clinical Trial Audits: The Independent, Risk-Triggered QA Instrument (Not Monitoring, Not an Inspection)

Clinical Quality Assurance Under ICH E6(R3): Build Quality In, Don't Audit It At Lock

Root Cause Analysis in Clinical Trials: How to Reach a Systemic Cause Your CAPA Can Actually Prevent

Critical-to-Quality Factors: A Living QbD Spine, Not a Protocol Appendix

GCP record retention: how long to keep clinical trial records and the TMF

Quality Tolerance Limits in Clinical Trials: How to Set, Breach, and Document 3-5 QTLs Under ICH E6(R3)

Serious Adverse Event Definition: What Makes an Event Serious

Clinical trial close-out procedures: the close-out visit as a verification gate

Phase 1 Drug Manufacturing: Exempt From Part 211, Not From CGMP

Central Lab vs Local Lab: What Changes Regulatorily

Electronic Data Capture in Clinical Trials: The GCP Accountability the Vendor Cannot Take From You

Source Documents in Clinical Trials: The ALCOA+ Evidence Layer, Certified Copies, and Risk-Based SDV

Quality by Design in Clinical Trials: A Critical-to-Quality (CtQ) Identification Workflow, Not a Philosophy Lecture

The Living Data Management Plan: A Risk-Based DMP Template That Survives Database Lock and Inspection

Query Management in Clinical Data Management: A Closure-Clock Playbook for One-Round Resolution

The Investigator Site File as an Inspection-Ready Evidence System: Reconciling the ISF to the TMF, and the Four Failure Modes Inspectors Cite

GCP Training Requirements: A Currency Status With an Expiry Date, Not a One-Time Certificate

Clinical Trial Database Lock: The Auditable State Machine (Soft Lock, Hard Lock, and the Controlled Unlock)

Principal Investigator Responsibilities: The Non-Delegable Accountability Boundary Under ICH E6(R3) and 21 CFR 312

Randomization and Blinding in Clinical Trials: One Bias-Control Chain From Allocation to Emergency Unblinding

The Ethics Committee Relationship: What an IRB/IEC Must Approve Before Enrollment and the Four Duties That Keep Approval Alive

The IRB Approval Lifecycle: Keeping Approval Continuously Valid Through Continuing Review, Amendments, and the Lapse You Must Avoid

IRB Continuing Review for Greater-Than-Minimal-Risk Studies: The Annual Floor, the Expiration Cliff, and What Still Needs Renewing

IRB Waiver of Consent: Three Decisions, Five Criteria, and What the 2024 FDA Rule Changed

Informed Consent Form Template: Build an Inspection-Ready ICF from the Required-Elements Checklist (ICH E6(R3) / 21 CFR 50)

What is a DSMB? The data safety monitoring board explained

Pharmacovigilance in Clinical Trials: The Classify-Then-Clock Workflow for AE, SAE, and SUSAR Reporting

SAE Reconciliation: A Field-Level Discrepancy-Resolution Workflow That Closes Before Lock and Never Lags the SUSAR Clock

Expedited Safety Reporting in Clinical Trials: The Four-Gate Clock for SAEs, SUSARs, and IND Safety Reports

Clinical Equipoise as a Monitorable Trial Condition: Who Owns It, When It Breaks, and What GCP Makes You Do

Essential documents in clinical trials: the ICH E6(R3) list and the test behind it

The eTMF, Operationalized: Completeness, Timeliness, and Quality That Survive a GCP Inspection

The Clinical Research Coordinator as a GCP-Accountability Map: Which CRC Duties Carry Regulatory Weight Under ICH E6(R3) and 21 CFR 312

EDC, eCRF, eCOA and IWRS as One Regulated Data Flow: Who Owns the Source Record and Where ALCOA Breaks at the Seams

Clinical Trial Design and Management as One Quality-by-Design Chain: From Critical-to-Quality Factors to Risk-Based Oversight

Clinical Trial Site Monitoring: The Visit-Type Lifecycle (SSV, SIV, IMV, COV) and the SIV Enrollment Gate

The TMF Reference Model as a Tailoring Exercise: Mapping DIA/CDISC Zones to ICH E6(R3) Essential Records

Clinical Trial Close-Out Checklist: A Dependency-Gated Sequence Built on GCP and 21 CFR Part 312

The Monitoring Visit Report as Oversight Evidence: A GCP-Audit-Ready MVR, Not a Filled-In Form

Data Safety Monitoring Plan vs. Medical Monitoring Plan vs. DSMB Charter: Which One Your Trial Needs, Who Signs It, and How They Fit Together

Protocol Deviation Management: An Impact-Classified Triage-and-Timeline Workflow Under ICH E6(R3) and 21 CFR 312

Risk-Based Monitoring in Clinical Trials: What It Is and What FDA and ICH E6(R3) Expect

The Quality-by-Design Clinical Trial Protocol: Engineering Out Deviations with Critical-to-Quality Factors and a Defensible Schedule of Activities

The Protocol Deviation Log, Engineered: Columns, Classification, and the Timelines an Inspector Reads as Control

Clinical Trial Endpoints as a Pre-Locked Contract: Who May See Endpoint and Interim Data, When, and What Counts as a Deviation

CTMS vs eTMF: Which System Is the System of Record (and Why GCP Findings Live on That Boundary)

Choosing an eTMF System That Survives a GCP Inspection: A Sponsor's Defensibility Framework

Screen Failure in Clinical Trials: How to Calculate the Rate, Document It Under GCP, and Read It as a Critical-to-Quality Signal

There Is No FDA IND Database: What You Can Actually Look Up, and How the Form-1571 IND Clock Really Works

IRB Approval, Decoded: Pick Your Review Tier Before You Submit (Exempt, Expedited, or Full Board)

Types of Audits in Clinical Trials: A Risk-Mapped Framework for Inspection Readiness

Clinical trial registration: who must register on ClinicalTrials.gov, and by when

TMF vs ISF: An Ownership-and-Reconciliation Contract, Not a Location Table

CAPA in Clinical Trials: The Four-Gate Workflow That Closes a Finding and Keeps It Closed

Electronic Data Capture Software: The Four GCP and Part 11 Obligations That Decide Whether 'Compliant' Survives an Inspection

ICH GCP After E6(R3): What the July 2025 Standard Requires Now, and How It Maps to FDA 21 CFR 312

The Trial Master File Checklist That Survives an Inspection: Completeness, Timeliness, and Quality Over a Document List

Central vs local IRB: when single-IRB review is required and who owns what after you sign

Vulnerable Populations in Clinical Research: A Triage-and-Safeguard Playbook (Not a List to Memorize)

Drug Accountability in Clinical Trials: Closing the Custody Chain Before the Inspector Opens the Log

From Word Template to Defensible Essential Document: Making an Informed Consent Form GCP-Compliant

What does a clinical research coordinator do? CRC duties and responsibilities

Remote Monitoring in Clinical Trials: Remote Site Monitoring Under ICH E6(R3) and FDA Guidance

Medical Monitor Responsibilities in Clinical Trials: The Four Safety Decisions, Their Reporting Clocks, and the Records That Prove Them

FDA DSUR Guidance: The DIBD-Anchored Annual Filing That Consolidates Your IND Annual Report (Not a Template)

Protocol Feasibility Assessment as an ICH E8 Quality-by-Design Gate: Run It on the Draft, Before Lock

Clinical Trial Terminology, Grouped by Workflow and Stamped to ICH E6(R3) (2025)

Clinical Trial Sponsor Responsibilities: The Non-Delegable Oversight System Under ICH E6(R3)

The Clinical Trial Agreement, Decoded: A Clause-by-Clause Negotiator's Playbook for the GCP Duties You Cannot Sign Away

The Delegation of Authority Log: Who Did What, and Whether They Were Qualified To

Risk-Based Quality Management (RBQM) in Clinical Trials: How the System Works Under ICH E6(R3)

The Clinical Study Report (CSR): ICH E3 Structure as a Reasoning Framework

The Clinical Monitoring Plan: A Risk-Based Blueprint, Not a Visit Schedule

SUSAR Reporting: Suspected, Unexpected, Serious, and the Clocks That Follow

Informed Consent in Clinical Trials: A Continuous Process, Not a Signature

Source Data Verification (SDV): Targeted, Risk-Based, and Paired With Source Data Review

Form FDA 1572: The Investigator's Binding Commitment, Not a Form-Fill

Adverse Event and SAE Reporting in Clinical Trials: One Decision Tree, Two Reporting Tracks

ALCOA and ALCOA+ Data Integrity in Clinical Trials: What the Acronym Actually Requires

What Is a Trial Master File (TMF)? Definition, Contents and the Test It Has to Pass

Protocol Deviations in Clinical Trials: Classify, Report, and Prevent Under ICH E6(R3)

Clinical trial budget management: the lines GCP and FDA rules fix

Clinical trial delays: which ones you can prevent and the control that heads off each

Drug development milestones: the FDA and EU gates between clinical trial phases

Audit trail requirements in clinical trials: what Part 11 demands and the review regulators expect

Clinical trial project management: the challenges that are really sponsor obligations

Clinical study start-up checklist: what must be true before each step

Clinical research SOPs: which ones a sponsor or site needs, and why

ICH E6(R3): What the Standard Contains and How to Navigate It

What is a CTMS? Clinical trial management systems and regulatory compliance

Clinical trial phases I to IV: what FDA rules and ICH E8(R1) say each phase is for

CTMS vs EDC: which records each system owns and what breaks between them

CRO and vendor oversight: what 21 CFR 312.52 transfers, what the sponsor keeps, and the records that prove it

Clinical Trial Site Feasibility: A Demonstration, Not a Questionnaire

Site initiation visit checklist: the GCP obligation and evidence behind each item

Clinical trial team structure: who is accountable and who does the work under GCP

Investigator-Initiated Studies: The Sponsor Duties You Take On

The Importance of Good Clinical Practice in Real-World Evidence Studies

Ethics in clinical trials: each principle and the provision that enforces it

Clinical Trial Data Integrity: Requirements at Every Stage of the Data Life Cycle

Principles of GCP: the definition of good clinical practice and the 11 ICH E6(R3) principles

The Elements of Informed Consent: What 21 CFR 50.25 Actually Requires

GCP Compliance: The Requirements and a Checklist of the Records That Prove Them

History of good clinical practice (GCP): a sourced timeline from Helsinki to E6(R3)

Data quality in clinical trials: what GCP means by fit for purpose